Novo nordisk Promotions under pressure after the general director leaves News ad

Novo nordisk a/s today

NPO

Novo Nordisk a/s.

$ 74.70 +2.05 (+2.82%)

As of 6/6/2025 20:59

52-week range

$ 57.00

▼

$ 148.15

Dividend yield

2.18%

P/e ratio.

22.71

Value is valuable

$ 128.00

Despite significant success as the chief executive director (general director) of the pharmaceutical giant Novo Nordisk A/S NYSE: NVOIN Lars Frugaard Jorgensen Located on auto. On May 16, Novaya announced that Jorgensen would resign. He will continue to head the company until the rule selects the new general director.

Jorgensen became the general director of Novo back in January 2017. From the end of January 2017 to May 16, Novy Nordisk reached a total profit of about 304%. This is significantly ahead of about 199% of the profitability of the S&P 500 index for this period. Nevertheless, the last 52 weeks or so were extremely rocky for new ones. As of the closure of June 3, 2025, shares decreased by almost 52% from their peak on June 25, 2024. Ultimately, the recent struggle of the company was too big to overcome Jèrgensen. So, what could cause Yorgensen’s departure, and What is next for new?

Jorgensen’s journey: which led to the dismissal of the Director General

For those who pay close attention to the drug market for reducing weight and diabetes, the recent difficulties of Novo Nordisk are not secret. The company quickly lost the market share of Eli Lilly and the company NYSE: Lly, The most valuable pharmaceutical action in the worldThe field of research has shown that Tyrzepatide Lilly reaches about 47% more weight loss than Semaglutide Novy. In addition, Lilly did a much better work to correct losing weight, helping to fill in the gap in the supply left by NOVO.

In the first quarter of 2024, Novo Wegovy and Ozempic sales amounted to about $ 5.6 billion. This is comparable to sales of 2.3 billion dollars for Lilly’s Zepbound and Mounjaro. This is approximately approximately 71% market share for Novo At that time. Based on the sales of these four drugs, this share fell to about 55% from the first quarter of 2025. The rapidly growing sales of Zepbound was an important reason for this.

The recent results of Lilly and NOVO to reduce weight development were the last nail in the coffin for Jorgensen. In December, Novo announced the results of the study in the field of accommodation and drugs of the phase 3 for experimental CAGISEMA preparations. The drug showed average weight loss 22.7% after 68 weeks. This was only higher than the average weight loss of 22.5%, which patients with tirzepatide reached after 72 weeks in the highest dose. It also missed expectations for weight loss of 25%. Novo shares fell sharply Almost 18% after the release of this news.

Then a new one released the results of CAGRISEMA for patients with obesity and diabetes of the type 2 of March 10, who once again disappointed investors. This led to the fact that the shares fell more than 9%. Meanwhile, Lilly met his expectations on his oral GLP-1, Orforglipron, for patients with type 2 diabetes. Promotions grew by more than 14% on April 17 as a result. Since June 25, 2024, Lilly shares receded much less than that of Novaya, only about 17%.

Next Director of Novo: American outsider? Healing in the United States can make this a logical choice

According to Reuters, the next hiring of the general director of the company will probably become the one who is currently not working in the company. Reuters interviewed six people, all of whom believe that the company will make a significant impetus for external hiring. Several analysts on Wall Stegdit believe that the company will reasonably hire an American. This will help the company negotiate with the Trump administration. The American CEO of Lilly, David Ricks, was skilled in this.

Such a step will make sense, given 57% Sales of Novo in the last quarter I arrived from the United States. About 69% of Wegovy and Ozempic sales came from the United States, which further emphasized the significance of the country for Novo. However, the company had only Danish leaders. A American hiring can create internal problems.

Nevertheless, whoever is the new general director compete with LillyThe company hopes that UBT251, the drug “Triple Agonist”, he bought the rights from United Laboratories International OTCMKTS: ULIHFcan do his job.

The path of the new one remains muddy; Augas -income can shed light

In general, the change in the main position of the new makes sense. Problems accelerated Lilly’s ability to significantly catch up in the well-known GLP-1 race between them. However, Lilly also deserves a large loan for its very effective treatment methods. At the moment, investors are largely waiting in limbo, when it comes to Novo shares. The company is as follows Reports on income on August 6.providing the opportunity to get more detailed information about your plans and overestimate sharesField

Before considering Novo Nordisk A/S, you will want to hear it.

Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before a wider market is won … and Novo Nordisk A/S was not on the list.

While Novo Nordisk A/S currently has a retention rating among analysts, analysts with the highest rating believe that these five promotions are better buying.

View five shares here

What shares will probably flourish in today’s complex market? Enter your email address, and we will send you a list of ten Marketbeat shares, which will move in any economic environment.

Get this free report

Like this article? Share this with a colleague.

The link is copied to the exchange buffer.